Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Y., Lin, Y., & Pang, J
Huber, D., Cha, M.-I., Debarbieux, L., Planson, A.-G., Lpez, G., Tasayco, M.L., Chaffotte, A., Beckwith, J
This product is not intended for diagnostic, therapeutic, or clinical use
Peer review Peer review information Nature Reviews Cancer thanks Katia Cosentino, who co-reviewed with Nadine Gehle, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work
Adult people ( 18 years) with a diagnosis of obesity (body mass index 30 kg/m 2 ) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users
Triple hormone receptor agonist reta for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial
US$ 21.50
US$ 29.28
US$ 24.53
US$ 25.84
US$ 24.73
